Evergreen Capital Management LLC Has $505,000 Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Evergreen Capital Management LLC boosted its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 7.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,097 shares of the specialty pharmaceutical company’s stock after buying an additional 273 shares during the period. Evergreen Capital Management LLC’s holdings in Jazz Pharmaceuticals were worth $505,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Bridgewater Associates LP grew its stake in Jazz Pharmaceuticals by 69.9% during the fourth quarter. Bridgewater Associates LP now owns 192,035 shares of the specialty pharmaceutical company’s stock worth $23,649,000 after purchasing an additional 79,036 shares during the period. Ontario Teachers Pension Plan Board increased its stake in shares of Jazz Pharmaceuticals by 79.5% in the 4th quarter. Ontario Teachers Pension Plan Board now owns 12,741 shares of the specialty pharmaceutical company’s stock valued at $1,569,000 after acquiring an additional 5,643 shares in the last quarter. Mariner LLC lifted its position in shares of Jazz Pharmaceuticals by 33.9% during the 4th quarter. Mariner LLC now owns 26,803 shares of the specialty pharmaceutical company’s stock valued at $3,301,000 after acquiring an additional 6,782 shares during the period. Barclays PLC boosted its stake in Jazz Pharmaceuticals by 70.2% during the fourth quarter. Barclays PLC now owns 66,728 shares of the specialty pharmaceutical company’s stock worth $8,216,000 after acquiring an additional 27,518 shares in the last quarter. Finally, Synovus Financial Corp grew its holdings in Jazz Pharmaceuticals by 0.5% in the fourth quarter. Synovus Financial Corp now owns 19,206 shares of the specialty pharmaceutical company’s stock worth $2,365,000 after purchasing an additional 100 shares during the period. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

Shares of Jazz Pharmaceuticals stock opened at $102.78 on Friday. The business’s fifty day simple moving average is $127.60 and its 200 day simple moving average is $122.32. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 12 month low of $95.49 and a 12 month high of $148.06. The firm has a market capitalization of $6.24 billion, a P/E ratio of 14.48, a price-to-earnings-growth ratio of 1.04 and a beta of 0.42.

Insider Activity

In other news, EVP Neena M. Patil sold 3,800 shares of the stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $144.87, for a total transaction of $550,506.00. Following the completion of the transaction, the executive vice president now directly owns 33,318 shares of the company’s stock, valued at $4,826,778.66. This represents a 10.24 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Bruce C. Cozadd sold 1,500 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $122.31, for a total transaction of $183,465.00. Following the sale, the chief executive officer now owns 439,744 shares of the company’s stock, valued at approximately $53,785,088.64. The trade was a 0.34 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 28,736 shares of company stock valued at $4,023,305 in the last ninety days. 4.20% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on JAZZ shares. Cantor Fitzgerald cut shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and increased their price objective for the stock from $140.00 to $150.00 in a research report on Wednesday, February 26th. HC Wainwright upped their target price on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a “buy” rating in a research report on Monday, March 10th. JPMorgan Chase & Co. lifted their price target on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. UBS Group upgraded shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $145.00 to $179.00 in a report on Friday, March 7th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $183.00 price objective (up from $175.00) on shares of Jazz Pharmaceuticals in a report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $187.71.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.